Johnson & Johnson Stock Price, News & Analysis (NYSE:JNJ)

$132.02 +2.11 (+1.62 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$132.02
Today's Range$130.02 - $132.08
52-Week Range$120.90 - $148.32
Volume5.12 million shs
Average Volume9.46 million shs
Market Capitalization$354.67 billion
P/E Ratio24.31
Dividend Yield2.55%
Beta0.74

About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logoJohnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Receive JNJ News and Ratings via Email

Sign-up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNYSE:JNJ
CUSIP47816010
Phone+1-732-5242455

Debt

Debt-to-Equity Ratio0.51%
Current Ratio1.41%
Quick Ratio1.02%

Price-To-Earnings

Trailing P/E Ratio24.3130755064457
Forward P/E Ratio16.28
P/E Growth2.18

Sales & Book Value

Annual Sales$76.45 billion
Price / Sales4.63
Cash Flow$9.71 per share
Price / Cash13.59
Book Value$22.42 per share
Price / Book5.89

Profitability

Trailing EPS$5.43
Net Income$1.30 billion
Net Margins1.70%
Return on Equity29.00%
Return on Assets13.13%

Miscellaneous

Employees126,400
Outstanding Shares2,682,900,000

Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson declared a quarterly dividend on Tuesday, January 2nd. Stockholders of record on Tuesday, February 27th will be given a dividend of $0.84 per share on Tuesday, March 13th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.55%. The ex-dividend date is Monday, February 26th. View Johnson & Johnson's Dividend History.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) released its earnings results on Tuesday, January, 23rd. The company reported $1.74 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.72 by $0.02. The business earned $20.20 billion during the quarter, compared to analysts' expectations of $20.08 billion. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. Johnson & Johnson's revenue was up 11.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.58 earnings per share. View Johnson & Johnson's Earnings History.

When will Johnson & Johnson make its next earnings announcement?

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, April, 17th 2018. View Earnings Estimates for Johnson & Johnson.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson issued an update on its FY18 earnings guidance on Tuesday, January, 23rd. The company provided earnings per share guidance of $8.00-8.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.87. The company issued revenue guidance of $80.6-81.4 billion, compared to the consensus revenue estimate of $80.71 billion.

Where is Johnson & Johnson's stock going? Where will Johnson & Johnson's stock price be in 2018?

18 equities research analysts have issued 12-month price objectives for Johnson & Johnson's stock. Their predictions range from $110.00 to $165.00. On average, they expect Johnson & Johnson's stock price to reach $145.59 in the next year. View Analyst Ratings for Johnson & Johnson.

What are Wall Street analysts saying about Johnson & Johnson stock?

Here are some recent quotes from research analysts about Johnson & Johnson stock:

  • 1. BTIG Research analysts commented, "Present – Starting to Outweigh Macro Tailwinds On Tuesday before market-open, JNJ reported 4Q17 financial results. In- line with our forecasting for the Pharma segment, the Actelion portfolio has begun to significantly disappoint expectations, Remicade erosion is accelerating, and mainstay franchises such as Imbruvica are beginning to moderate growth. The major discussion point we have had with investors is whether our negative Pharma thesis can trump the positive macro factors. We continue to think so, despite tailwinds such as tax reform helping the stock and overall stock market during 2H2017. At the end of the day, Pharma drives over 50% of total profit generation for the company. We reiterate our Sell rating and $110 PT.   We forecast 1Q18 as the peak of recent Pharma growth and expect a mirror image of 2017 for the remainder of the year, whereby growth will moderate significantly into 2H2018: Our forecast calls for Pharma operational growth of +9.2%/ 6.3%/ 5.1%/ 4.3% during 1Q – 4Q2018, and we now explicitly include the approval of apalutamide within our forecasts (drug model inside report).   Remicade erosion starting to become impactful and deteriorating pricing is likely affecting overall company gross margins: Mgmt noted that volumes for Remicade were generally steady during 4Q17, but this has come at the expense of pricing declines, which is a pure hit to product margins. Our best estimate is that the price erosion of Remicade negatively impacted overall company gross margins by – 30bps YoY during 4Q17." (1/24/2018)
  • 2. According to Zacks Investment Research, "Sales in J&J’s domestic Pharma segment decelerated in the first half of 2017 as a number of key growth drivers like Remicade and Concerta are facing competition.  However, sales growth accelerated in Q3 and the positive trend is expected to continue in Q4. We believe that new products in all segments, label expansion of drugs like Imbruvica and Darzalex and contribution from recent acquisitions - mainly Actelion – can support top-line growth.  Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. J&J’s shares have outperformed the industry this year so far.  However, headwinds like generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment is also a concern." (12/12/2017)

Who are some of Johnson & Johnson's key competitors?

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the folowing people:

  • Alex Gorsky, Chairman of the Board, Chief Executive Officer (Age 56)
  • Dominic J. Caruso, Chief Financial Officer, Executive Vice President (Age 59)
  • Peter M. Fasolo Ph.D., Chief Human Resource Officer, Executive Vice President (Age 54)
  • Paulus A. Stoffels, Executive Vice President, Chief Scientific Officer (Age 55)
  • Michael H. Ullmann, Executive Vice President, General Counsel (Age 58)
  • Joaquin Duato, Executive Vice President, Worldwide Chairman - Pharmaceuticals (Age 54)
  • Jorge S. Mesquita, Executive Vice President, Worldwide Chairman - Consumer (Age 55)
  • Sandra E. Peterson, Executive Vice President - Group Worldwide Chairman (Age 58)
  • Joseph Wolk, Vice President - Investor Relations
  • Anne M. Mulcahy, Lead Independent Director (Age 64)

Who owns Johnson & Johnson stock?

Johnson & Johnson's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.24%), Bank of New York Mellon Corp (1.35%), Geode Capital Management LLC (1.14%), TIAA CREF Investment Management LLC (0.47%), Schwab Charles Investment Management Inc. (0.47%) and Fisher Asset Management LLC (0.45%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.

Who sold Johnson & Johnson stock? Who is selling Johnson & Johnson stock?

Johnson & Johnson's stock was sold by a variety of institutional investors in the last quarter, including Credit Agricole S A, PGGM Investments, Caisse DE Depot ET Placement DU Quebec, BlackRock Inc., Metropolitan Life Insurance Co. NY, American Century Companies Inc., Renaissance Technologies LLC and Calamos Advisors LLC. Company insiders that have sold Johnson & Johnson company stock in the last year include Dominic J Caruso and Paulus Stoffels. View Insider Buying and Selling for Johnson & Johnson.

Who bought Johnson & Johnson stock? Who is buying Johnson & Johnson stock?

Johnson & Johnson's stock was bought by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Mackenzie Financial Corp, UBS Asset Management Americas Inc., Geode Capital Management LLC, Investec Asset Management LTD, MetLife Investment Advisors LLC, Cornerstone Investment Partners LLC and Teachers Advisors LLC. View Insider Buying and Selling for Johnson & Johnson.

How do I buy Johnson & Johnson stock?

Shares of Johnson & Johnson can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Johnson & Johnson's stock price today?

One share of Johnson & Johnson stock can currently be purchased for approximately $132.02.

How big of a company is Johnson & Johnson?

Johnson & Johnson has a market capitalization of $354.67 billion and generates $76.45 billion in revenue each year. The company earns $1.30 billion in net income (profit) each year or $5.43 on an earnings per share basis. Johnson & Johnson employs 126,400 workers across the globe.

How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is 1 Johnson And Johnson Plz, NEW BRUNSWICK, NJ 08933-0001, United States. The company can be reached via phone at +1-732-5242455.


MarketBeat Community Rating for Johnson & Johnson (JNJ)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  524 (Vote Outperform)
Underperform Votes:  636 (Vote Underperform)
Total Votes:  1,160
MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Johnson & Johnson (NYSE:JNJ) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.222.222.322.28
Ratings Breakdown: 4 Sell Rating(s)
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
5 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
7 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $145.59$145.59$143.56$132.25
Price Target Upside: 2.65% upside2.65% upside0.81% upside0.48% downside

Johnson & Johnson (NYSE:JNJ) Consensus Price Target History

Price Target History for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2018Stifel NicolausBoost Price TargetHold -> Hold$142.00 -> $145.00LowView Rating Details
1/24/2018BTIG ResearchReiterated RatingSell$110.00LowView Rating Details
1/22/2018Credit Suisse GroupSet Price TargetHold$154.00HighView Rating Details
1/12/2018Wells Fargo & CoReiterated RatingOutperform -> Outperform$155.00 -> $160.00LowView Rating Details
1/9/2018Royal Bank of CanadaReiterated RatingBuyLowView Rating Details
1/2/2018JPMorgan Chase & Co.DowngradeOverweight -> NeutralLowView Rating Details
12/12/2017BMO Capital MarketsBoost Price TargetOutperform$161.00MediumView Rating Details
10/23/2017CitigroupBoost Price TargetBuy$140.00 -> $149.00N/AView Rating Details
10/16/2017Jefferies GroupBoost Price TargetBuy$157.00 -> $160.00N/AView Rating Details
10/18/2017BarclaysBoost Price TargetEqual Weight$140.00 -> $148.00N/AView Rating Details
10/18/2017CowenReiterated RatingOutperform$147.00 -> $155.00N/AView Rating Details
10/18/2017Morgan StanleyReiterated RatingHold$140.00 -> $145.00N/AView Rating Details
10/18/2017ArgusBoost Price TargetBuy -> Positive$145.00 -> $165.00N/AView Rating Details
10/18/2017Leerink SwannReiterated RatingOutperform -> Outperform$150.00 -> $165.00N/AView Rating Details
10/4/2017Piper Jaffray CompaniesReiterated RatingHold$120.00LowView Rating Details
9/20/2017Goldman Sachs GroupDowngradeNeutral -> Sell$125.00 -> $130.00LowView Rating Details
7/21/2017Alembic Global AdvisorsDowngradeNeutral -> UnderweightLowView Rating Details
7/21/2017Atlantic SecuritiesDowngradeNeutral -> Underweight$113.00LowView Rating Details
11/28/2016Bank of AmericaReiterated RatingHold$126.00N/AView Rating Details
10/23/2016Societe GeneraleReiterated RatingHold$116.00N/AView Rating Details
8/19/2016Deutsche BankReiterated RatingBuy$142.00N/AView Rating Details
5/20/2016Raymond James FinancialReiterated RatingOutperform$120.00N/AView Rating Details
5/20/2016Standpoint ResearchInitiated CoverageSell$94.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Johnson & Johnson (NYSE:JNJ) Earnings History and Estimates Chart

Earnings by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE JNJ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/17/2018N/AView Earnings Details
1/23/2018Q4 2017$1.72$1.74$20.08 billion$20.20 billionViewListenView Earnings Details
10/17/2017Q3 2017$1.80$1.90$19.29 billion$19.65 billionViewN/AView Earnings Details
7/18/2017Q2 2017$1.79$1.83$18.94 billion$18.84 billionViewN/AView Earnings Details
4/18/2017Q1 17$1.77$1.83$18.02 billion$17.77 billionViewN/AView Earnings Details
1/24/2017Q416$1.56$1.58$18.28 billion$18.10 billionViewN/AView Earnings Details
10/18/2016Q316$1.65$1.68$17.71 billion$17.80 billionViewListenView Earnings Details
7/19/2016Q216$1.68$1.74$17.98 billion$18.50 billionViewListenView Earnings Details
4/19/2016Q116$1.65$1.68$17.50 billion$17.50 billionViewListenView Earnings Details
1/26/2016Q415$1.42$1.44$17.88 billion$17.80 billionViewListenView Earnings Details
10/13/2015Q315$1.45$1.49$17.47 billion$17.10 billionViewListenView Earnings Details
7/14/2015Q215$1.69$1.71$17.76 billion$17.80 billionViewListenView Earnings Details
4/14/2015Q115$1.54$1.56$17.31 billion$17.37 billionViewListenView Earnings Details
1/20/2015Q414$1.25$1.27$18.59 billion$18.30 billionViewListenView Earnings Details
10/14/2014Q314$1.42$1.50$18.41 billion$18.50 billionViewListenView Earnings Details
7/15/2014Q214$1.54$1.66$18.86 billion$19.50 billionViewN/AView Earnings Details
4/15/2014Q114$1.48$1.54$18.00 billion$18.10 billionViewN/AView Earnings Details
1/21/2014Q413$1.20$1.24$17.95 billion$18.40 billionViewN/AView Earnings Details
10/15/2013Q313$1.32$1.36$17.46 billion$17.60 billionViewN/AView Earnings Details
7/16/2013Q2 2013$1.39$1.48$17.71 billion$17.90 billionViewN/AView Earnings Details
4/16/2013Q1 2013$1.41$1.44$17.46 billion$17.50 billionViewN/AView Earnings Details
1/22/2013Q4 2012$1.17$1.19$17.67 billion$17.60 billionViewN/AView Earnings Details
10/16/2012$1.21$1.25ViewN/AView Earnings Details
7/17/2012$1.29$1.30ViewN/AView Earnings Details
4/17/2012$1.34$1.37ViewN/AView Earnings Details
1/24/2012$1.09$1.13ViewN/AView Earnings Details
10/18/2011$1.21$1.24ViewN/AView Earnings Details
7/19/2011$1.24$1.28ViewN/AView Earnings Details
4/19/2011$1.26$1.35ViewN/AView Earnings Details
1/25/2011$1.03$1.03ViewN/AView Earnings Details
10/19/2010Q3 2010$1.15$1.23ViewN/AView Earnings Details
7/20/2010Q2 2010$1.21$1.21ViewN/AView Earnings Details
4/20/2010Q1 2010$1.27$1.29ViewN/AView Earnings Details
1/26/2010Q4 2009$0.97$1.02ViewN/AView Earnings Details
10/13/2009Q3 2009$1.13$1.20ViewN/AView Earnings Details
7/14/2009Q2 2009$1.12$1.15ViewN/AView Earnings Details
4/14/2009Q1 2009$1.21$1.26ViewN/AView Earnings Details
1/20/2009Q4 2008$0.92$0.94ViewN/AView Earnings Details
10/14/2008Q3 2008$1.11$1.17ViewN/AView Earnings Details
7/15/2008Q2 2008$1.13$1.18ViewN/AView Earnings Details
4/15/2008Q1 2008$1.20$1.26ViewN/AView Earnings Details
1/22/2008Q4 2007$0.86$0.88ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Johnson & Johnson (NYSE:JNJ) Earnings Estimates

2018 EPS Consensus Estimate: $8.10
2019 EPS Consensus Estimate: $8.66
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$1.99$1.99$1.99
Q2 20181$2.06$2.06$2.06
Q3 20181$1.97$1.97$1.97
Q4 20181$2.08$2.08$2.08
Q1 20191$2.16$2.16$2.16
Q2 20191$2.22$2.22$2.22
Q3 20191$2.11$2.11$2.11
Q4 20191$2.17$2.17$2.17
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Johnson & Johnson (NYSE:JNJ) Dividend Information

Next Dividend:3/13/2018
Annual Dividend:$3.36
Dividend Yield:2.55%
Dividend Growth:6.40% (3 Year Average)
Payout Ratio:61.88% (Trailing 12 Months of Earnings)
41.43% (Based on This Year's Estimates)
38.93% (Based on Next Year's Estimates)
Track Record:55 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/2/2018quarterly$0.842.39%2/26/20182/27/20183/13/2018
10/19/2017quarterly$0.842.37%11/27/201711/28/201712/12/2017
7/17/2017quarterly$0.842.5%8/25/20178/29/20179/12/2017
4/27/2017quarterly$0.842.72%5/25/20175/30/20176/13/2017
1/3/2017quarterly$0.802.77%2/24/20172/28/20173/14/2017
10/20/2016quarterly$0.8011/18/201611/22/201612/6/2016
7/18/2016quarterly$0.808/19/20168/23/20169/6/2016
4/28/2016quarterly$0.805/20/20165/24/20166/7/2016
1/4/2016quarterly$0.752/19/20162/23/20163/8/2016
10/22/2015quarterly$0.7511/20/201511/24/201512/8/2015
7/20/2015quarterly$0.758/21/20158/25/20159/8/2015
4/23/2015quarterly$0.752.97%5/21/20155/26/20156/9/2015
1/5/2015quarterly$0.702.71%2/20/20152/24/20153/10/2015
10/16/2014quarterly$0.702.89%11/21/201411/25/201412/9/2014
7/21/2014quarterly$0.702.73%8/22/20148/26/20149/9/2014
4/24/2014quarterly$0.702.81%5/22/20145/27/20146/10/2014
1/2/2014quarterly$0.662.87%2/21/20142/25/20143/11/2014
10/17/2013quarterly$0.662.88%11/22/201311/26/201312/10/2013
7/15/2013quarterly$0.662.92%8/23/20138/27/20139/10/2013
4/25/2013quarterly$0.663.1%5/23/20135/28/20136/11/2013
1/2/2013quarterly$0.613.45%2/22/20132/26/20133/12/2013
(Data available from 1/1/2013 forward)

Insider Trades

Johnson & Johnson (NYSE JNJ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 65.58%
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE JNJ) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2018Paulus StoffelsVPSell155,342$129.86$20,172,712.12357,906View SEC Filing  
7/24/2017Paulus StoffelsVPSell102,692$133.14$13,672,412.88230,342View SEC Filing  
7/20/2017Dominic J CarusoVPSell82,591$136.72$11,291,841.52226,693View SEC Filing  
2/15/2017Paulus StoffelsVPSell22,000$117.29$2,580,380.00127,650View SEC Filing  
10/21/2016Charles PrinceDirectorBuy875$114.11$99,846.2526,520View SEC Filing  
7/26/2016Dominic J CarusoVPSell41,146$125.01$5,143,661.46157,819View SEC Filing  
7/22/2016Ronald A KapustaCAOSell2,935$125.01$366,904.3528,660View SEC Filing  
6/7/2016Gary J PrudenVPSell9,735$116.03$1,129,552.0543,630View SEC Filing  
6/7/2016Ronald A KapustaCAOSell3,000$115.79$347,370.0028,725View SEC Filing  
5/10/2016Ronald A KapustaCAOSell3,957$114.77$454,144.8929,682View SEC Filing  
2/17/2016Paulus StoffelsinsiderSell125,000$102.43$12,803,750.00122,543View SEC Filing  
2/3/2016Peter FasoloVPSell151,385$104.12$15,762,206.2037,735View SEC Filing  
10/23/2015Ronald A. KapustaCAOSell6,239$99.68$621,903.5220,803View SEC Filing  
6/2/2015Charles PrinceDirectorBuy2,500$99.22$248,050.00View SEC Filing  
4/28/2015Paulus StoffelsInsiderSell187,250$100.73$18,861,692.50View SEC Filing  
9/10/2014James CullenDirectorSell2,446$104.12$254,677.52View SEC Filing  
5/5/2014Stephen CosgroveInsiderSell22,000$100.05$2,201,100.0090,294View SEC Filing  
3/14/2014Peter FasoloVPSell6,824$93.15$635,655.6015,647View SEC Filing  
8/14/2013Stephen CosgroveInsiderSell17,200$91.39$1,571,908.0088,159View SEC Filing  
8/5/2013Michael UllmannVPSell16,140$93.68$1,511,995.2055,427View SEC Filing  
7/25/2013Paulus StoffelsInsiderSell45,440$92.40$4,198,656.00View SEC Filing  
7/18/2013Dominic J CarusoCFOSell30,000$90.31$2,709,300.00View SEC Filing  
11/12/2012James CullenDirectorSell13,900$69.70$968,830.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Johnson & Johnson (NYSE JNJ) News Headlines

Source:
DateHeadline
JNJ INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Johnson ... - Business Wire (press release)JNJ INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Johnson ... - Business Wire (press release)
www.businesswire.com - February 24 at 8:04 AM
Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for February 26, 2018 - NasdaqJohnson & Johnson (JNJ) Ex-Dividend Date Scheduled for February 26, 2018 - Nasdaq
www.nasdaq.com - February 24 at 8:04 AM
[$$] MKM Raises Amazon.com Price Target by 30%[$$] MKM Raises Amazon.com Price Target by 30%
finance.yahoo.com - February 24 at 8:04 AM
3 Big Drugmakers Boosting Huge R&D Budgets3 Big Drugmakers Boosting Huge R&D Budgets
finance.yahoo.com - February 24 at 8:04 AM
Texas Yale Capital Corp. Sells 584 Shares of Johnson & Johnson (JNJ)Texas Yale Capital Corp. Sells 584 Shares of Johnson & Johnson (JNJ)
www.americanbankingnews.com - February 24 at 4:16 AM
D.A. Davidson & CO. Grows Stake in Johnson & Johnson (JNJ)D.A. Davidson & CO. Grows Stake in Johnson & Johnson (JNJ)
www.americanbankingnews.com - February 24 at 4:16 AM
Rodgers Brothers Inc. Has $8.81 Million Holdings in Johnson & Johnson (JNJ)Rodgers Brothers Inc. Has $8.81 Million Holdings in Johnson & Johnson (JNJ)
www.americanbankingnews.com - February 24 at 4:16 AM
Johnson & Johnson (JNJ) Holdings Raised by Pinnacle Financial Partners Inc.Johnson & Johnson (JNJ) Holdings Raised by Pinnacle Financial Partners Inc.
www.americanbankingnews.com - February 24 at 4:16 AM
Cannell Peter B & Co. Inc. Reduces Stake in Johnson & Johnson (JNJ)Cannell Peter B & Co. Inc. Reduces Stake in Johnson & Johnson (JNJ)
www.americanbankingnews.com - February 24 at 4:16 AM
Wasatch Advisors Inc. Has $10.77 Million Holdings in Johnson & Johnson (JNJ)Wasatch Advisors Inc. Has $10.77 Million Holdings in Johnson & Johnson (JNJ)
www.americanbankingnews.com - February 24 at 4:16 AM
Zurcher Kantonalbank Zurich Cantonalbank Acquires 12,608 Shares of Johnson & Johnson (JNJ)Zurcher Kantonalbank Zurich Cantonalbank Acquires 12,608 Shares of Johnson & Johnson (JNJ)
www.americanbankingnews.com - February 24 at 4:16 AM
Assetmark Inc. Reduces Stake in Johnson & Johnson (JNJ)Assetmark Inc. Reduces Stake in Johnson & Johnson (JNJ)
www.americanbankingnews.com - February 24 at 4:16 AM
Jim Cramer: You Have to Decide If You Want to Profit From This MomentJim Cramer: You Have to Decide If You Want to Profit From This Moment
finance.yahoo.com - February 23 at 6:08 PM
Pawar Law Group Announces That a Class Action Lawsuit Has Been Filed On Behalf of Shareholders Who Purchased Shares of Johnson & Johnson (NYSE: JNJ) Between February 22, 2013 and February 7, 2018, Both Dates InclusivePawar Law Group Announces That a Class Action Lawsuit Has Been Filed On Behalf of Shareholders Who Purchased Shares of Johnson & Johnson (NYSE: JNJ) Between February 22, 2013 and February 7, 2018, Both Dates Inclusive
finance.yahoo.com - February 23 at 6:08 PM
JNJ INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Johnson & Johnson and a Lead Plaintiff Deadline of April 9, 2018JNJ INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Johnson & Johnson and a Lead Plaintiff Deadline of April 9, 2018
finance.yahoo.com - February 23 at 6:08 PM
JNJ SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action ... - GlobeNewswire (press release)JNJ SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action ... - GlobeNewswire (press release)
globenewswire.com - February 23 at 8:08 AM
Why Is Johnson & Johnson (JNJ) Down 8.5% Since its Last Earnings Report? - NasdaqWhy Is Johnson & Johnson (JNJ) Down 8.5% Since its Last Earnings Report? - Nasdaq
www.nasdaq.com - February 23 at 8:08 AM
Performance of Johnson & Johnson’s Remicade and Stelara in 2017Performance of Johnson & Johnson’s Remicade and Stelara in 2017
finance.yahoo.com - February 23 at 8:08 AM
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Johnson & Johnson To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action LawsuitINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Johnson & Johnson To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
finance.yahoo.com - February 22 at 5:44 PM
Why Is Johnson & Johnson (JNJ) Down 8.5% Since its Last Earnings Report?Why Is Johnson & Johnson (JNJ) Down 8.5% Since its Last Earnings Report?
finance.yahoo.com - February 22 at 5:44 PM
JNJ SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Johnson & Johnson and a Lead Plaintiff Deadline of April 9, 2018JNJ SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Johnson & Johnson and a Lead Plaintiff Deadline of April 9, 2018
finance.yahoo.com - February 22 at 5:44 PM
February Pharma And Biotech Dividend Stocks To Look Out ForFebruary Pharma And Biotech Dividend Stocks To Look Out For
finance.yahoo.com - February 22 at 8:08 AM
Why TG Therapeutics Stock Jumped 10% TodayWhy TG Therapeutics Stock Jumped 10% Today
finance.yahoo.com - February 21 at 5:34 PM
Johnson & Johnson to start vertical construction on $18M Lake Nona facilityJohnson & Johnson to start vertical construction on $18M Lake Nona facility
finance.yahoo.com - February 21 at 5:34 PM
Johnson & Johnson (JNJ) Said to Explore Sale of $2 Billion Sterilization Division - StreetInsider.comJohnson & Johnson (JNJ) Said to Explore Sale of $2 Billion Sterilization Division - StreetInsider.com
www.streetinsider.com - February 21 at 8:09 AM
Can Johnson & Johnson Replace Remicade for $100 Million Upfront?Can Johnson & Johnson Replace Remicade for $100 Million Upfront?
finance.yahoo.com - February 21 at 8:09 AM
Insider Selling: Johnson & Johnson (JNJ) VP Sells 155,342 Shares of StockInsider Selling: Johnson & Johnson (JNJ) VP Sells 155,342 Shares of Stock
www.americanbankingnews.com - February 20 at 9:10 PM
See what the IHS Markit Score report has to say about Johnson & Johnson.See what the IHS Markit Score report has to say about Johnson & Johnson.
finance.yahoo.com - February 20 at 5:55 PM
JNJ INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Johnson & Johnson InvestorsJNJ INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Johnson & Johnson Investors
finance.yahoo.com - February 20 at 5:55 PM
Johnson & Johnson to Participate in Cowen 38th Annual Healthcare ConferenceJohnson & Johnson to Participate in Cowen 38th Annual Healthcare Conference
finance.yahoo.com - February 20 at 5:55 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Johnson & Johnson of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 9, 2018 – JNJSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Johnson & Johnson of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 9, 2018 – JNJ
feeds.benzinga.com - February 20 at 3:45 PM
Your Daily Pharma Scoop: AbbVies Upadacitinib, Johnson & Johnsons Tremfya, Celgene Reports Results For Otezla - Seeking AlphaYour Daily Pharma Scoop: AbbVie's Upadacitinib, Johnson & Johnson's Tremfya, Celgene Reports Results For Otezla - Seeking Alpha
seekingalpha.com - February 20 at 8:09 AM
J&J Is Exploring a Sale of Its $2 Billion Sterilization DivisionJ&J Is Exploring a Sale of Its $2 Billion Sterilization Division
finance.yahoo.com - February 20 at 8:08 AM
This Blue-Chip Healthcare Stock Deserves a Gold Medal for Its Financial FortitudeThis Blue-Chip Healthcare Stock Deserves a Gold Medal for Its Financial Fortitude
finance.yahoo.com - February 17 at 5:06 PM
Johnson & Johnsons Tremfya shows sustained treatment effect in late-stage psoriasis study - Seeking AlphaJohnson & Johnson's Tremfya shows sustained treatment effect in late-stage psoriasis study - Seeking Alpha
seekingalpha.com - February 17 at 8:06 AM
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Johnson & JohnsonThe Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Johnson & Johnson
finance.yahoo.com - February 16 at 5:24 PM
Aimovig as Prophylaxis Therapy in Chronic and Episodic MigraineAimovig as Prophylaxis Therapy in Chronic and Episodic Migraine
finance.yahoo.com - February 16 at 5:24 PM
How Cosentyx Resolves Enthesitis in Psoriatic Arthritis PatientsHow Cosentyx Resolves Enthesitis in Psoriatic Arthritis Patients
finance.yahoo.com - February 16 at 5:24 PM
Stocks stretch winning streak to 6 days despite turbulenceStocks stretch winning streak to 6 days despite turbulence
finance.yahoo.com - February 16 at 5:24 PM
Markets Right Now: Stocks rise for the 6th straight dayMarkets Right Now: Stocks rise for the 6th straight day
marketbeat.com - February 16 at 4:12 PM
Johnson & Johnson Consumer Presents New Scientific Research At 2018 American Academy of Dermatology Annual MeetingJohnson & Johnson Consumer Presents New Scientific Research At 2018 American Academy of Dermatology Annual Meeting
www.prnewswire.com - February 16 at 10:38 AM
Glancy Prongay & Murray LLP Continues Investigation on Behalf of ... - Business Wire (press release)Glancy Prongay & Murray LLP Continues Investigation on Behalf of ... - Business Wire (press release)
www.businesswire.com - February 16 at 8:08 AM
UPDATE: Johnson & Johnson (JNJ) Janssen gains FDA approval for Erleada for certain prostate cancers - StreetInsider.comUPDATE: Johnson & Johnson (JNJ) Janssen gains FDA approval for Erleada for certain prostate cancers - StreetInsider.com
www.streetinsider.com - February 16 at 8:08 AM
J&J (JNJ) Gets FDA Nod for New Prostrate Cancer TreatmentJ&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment
finance.yahoo.com - February 15 at 5:27 PM
Glancy Prongay & Murray LLP Continues Investigation on Behalf of Johnson & Johnson Investors (JNJ)Glancy Prongay & Murray LLP Continues Investigation on Behalf of Johnson & Johnson Investors (JNJ)
finance.yahoo.com - February 15 at 5:27 PM
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Johnson & JohnsonThe Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Johnson & Johnson
finance.yahoo.com - February 15 at 5:27 PM
Why I Recently Bought Johnson & JohnsonWhy I Recently Bought Johnson & Johnson
seekingalpha.com - February 15 at 8:37 AM
ONGOING INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Johnson & JohnsonONGOING INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Johnson & Johnson
finance.yahoo.com - February 15 at 8:37 AM
How Analysts View Bristol-Myers Squibb after Its 4Q17 EarningsHow Analysts View Bristol-Myers Squibb after Its 4Q17 Earnings
finance.yahoo.com - February 15 at 8:37 AM
Today’s Research Reports on Trending Tickers: Johnson & Johnson and Merck & CompanyToday’s Research Reports on Trending Tickers: Johnson & Johnson and Merck & Company
finance.yahoo.com - February 15 at 8:37 AM

SEC Filings

Johnson & Johnson (NYSE:JNJ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Johnson & Johnson (NYSE:JNJ) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Johnson & Johnson (NYSE JNJ) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.